Zynyz Approved for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma
The FDA has granted accelerated approval to Zynyz (retifanlimab) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
The FDA has granted accelerated approval to Zynyz (retifanlimab) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
Military pilots and the ground crews who fuel and maintain their aircraft have higher rates of certain cancers, a new study shows.
Adolescent and young adult patients diagnosed with cancer during pregnancy have a higher risk of adverse birth outcomes, a study suggests.
Patients with high-risk, stage III melanoma have similar outcomes whether they undergo surgery upfront or receive immunotherapy prior to surgery, a study suggests.
Oral nicotinamide does not reduce the risk of keratinocyte cancers in organ transplant recipients, a study suggests.
Authors present a concise overview of the diagnosis, risk factors, and treatment of basal cell carcinoma.
Personalized ctDNA monitoring can predict outcomes during and after treatment in patients with advanced melanoma, a study suggests.
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
Periadjuvant pembrolizumab may improve outcomes over adjuvant pembrolizumab alone in patients with resectable stage III-IV melanoma, a phase 2 study suggests.
A novel method of treating immune checkpoint inhibitor-associated myocarditis may decrease the risk of death from myotoxicity.